Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICP-923
- Development stage
- Preclinical
- Lead developer
- Innocare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ICP-923 is an oral small molecule drug developed by InnoCare Pharma. It acts as a potent IL-17A blocker, targeting the IL-17 receptor family. IL-17 is a pro-inflammatory cytokine that plays a key role in immune functional responses and the pathogenesis of various autoimmune diseases. Unlike monoclonal antibodies that target IL-17, ICP-923 offers the convenience of oral administration and can potently block both IL-17AA and IL-17AF binding to the IL-17 receptor[4][5]. As of June 2025, its highest development status is preclinical for autoimmune diseases[1][4].
02
Targets
IL17RA (IL-17RA)IL-17A (Interleukin-17A)IL-17R (Interleukin 17 Receptor)
Beyond the preview
Go deeper on ICP-923.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICP-923.